Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26B1 | Q9NR63 | 6/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.50 |
| ▸ | RXRA | P19793 | 4/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | RARA | P10276 | 2/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142134 | 0.95 | CYP26B1 (0.49) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL7143302 | 0.93 | CYP26A1 (0.48) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL2897524 | 0.89 | CYP26B1 (0.53) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL4668411 | 0.84 | CYP26B1 (0.52) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL9770704 | 0.83 | SKP2 (0.45) | CYP26B1CYP26A1RXRASKP2CYP3A4 | |
| SCHEMBL3176733 | 0.81 | RXRA (0.54) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL7207050 | 0.80 | SKP2 (0.42) | RXRASKP2NPC1HPGDMAPK1 | |
| SCHEMBL4365965 | 0.80 | CYP26B1 (0.55) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL16998630 | 0.80 | CYP26B1 (0.51) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL11240978 | 0.80 | CYP26B1 (0.51) | CYP26B1CYP26A1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5466690-A | Treating psoriasis | ALLERGAN, INC. (US) | 1995-11-14 | — | — | US | disclosed |
| US-5354776-A | Treating psoriasis | ALLERGAN, INC. (US) | 1994-10-11 | — | — | US | disclosed |
| CN-1025612-C | Process for preparing acetylene R disubstituted by heteroaryl and tetralin | ALLERGAN INC (US) | 1994-08-10 | — | — | CN | disclosed |
| EP-0284261-B1 | Acetylenes disubstituted with a heteroaromatic group and a tetralin group having retinoid like activity | ALLERGAN INC (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5246962-A | Psoriasis, skin disorders | ALLERGAN, INC. (US) | 1993-09-21 | — | — | US | disclosed |
| US-5149705-A | Treatment of psoriasis | ALLERGAN, INC. (US) | 1992-09-22 | — | — | US | disclosed |
| EP-0284261-A1 | Acetylenes disubstituted with a heteroaromatic group and a tetralin group having retinoid like activity | ALLERGAN, INC (US) | 1988-09-28 | — | — | EP | disclosed |
| CN-88101234-A | Acetylenes disubstituted with heteroaryl and tetralinyl having retinoid-like activity | — | 1988-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | CYP26B1 311/4885CYP26A1 420/4885RXRA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.